# v4.2 final safety check

Checked manuscript:

- `manuscript/LOX_thymus_aging_public_preprint_v4_2_final_safe.md`

Inputs used:

- `manuscript/LOX_thymus_aging_public_preprint_v4_1_safe.md`
- `reports/v4_1_hostile_reaudit.md`

## Applied final wording fixes

The two remaining hostile-reviewer wording concerns were addressed.

1. Abstract candidate language was softened.

Original v4.1 phrase:

> with `Loxl2` emerging as the most recurrent candidate transcript marker requiring protein, spatial, enzymatic, and functional validation

Final v4.2 phrase:

> with `Loxl2` emerging as a recurrent candidate transcript marker requiring orthogonal experimental follow-up

2. Ranking/promotional language was removed.

Original v4.1 sentence:

> The most prominent epithelial LOX-family candidate in this analysis was aged-lower `Loxl2` in mTEC1.

Final v4.2 sentence:

> An epithelial LOX-family candidate in this analysis was aged-lower `Loxl2` in mTEC1.

Original v4.1 sentence:

> `Loxl2` is the most recurrent LOX-family candidate transcript in this analysis.

Final v4.2 sentence:

> `Loxl2` appeared repeatedly across the transcript-level summaries in this analysis.

## Requested risky-phrase scan

| phrase | result | interpretation |
|---|---:|---|
| `most prominent` | 0 matches | Pass. |
| `most recurrent` | 0 matches | Pass. |
| `functional validation` | 0 matches | Pass. |
| `possible mediator` | 0 matches | Pass. |
| `strongest` | 0 matches | Pass. |
| `validated` | 0 matches | Pass. |
| `proves` | 0 matches | Pass. |
| `therapeutic` | 0 matches | Pass. |
| `rejuvenation` | 1 match | Acceptable: limitation wording, not a claim of rejuvenation. |

The remaining `rejuvenation` hit is:

> Fourth, transcript abundance does not establish protein abundance, protein localization, secretion, LOX enzymatic activity, extracellular matrix composition, collagen or elastin crosslinking, tissue mechanics, thymic rejuvenation, or functional consequences.

This is an explicit limitation and is acceptable.

## Final safety confirmations

| safety criterion | status | note |
|---|---|---|
| No causal claim | Pass | The manuscript explicitly says the analysis does not show `Loxl2` is causal and does not resolve causality. |
| No protein-level claim | Pass | Protein is mentioned only as background or as something not established / requiring future work. |
| No enzymatic activity claim | Pass | Enzymatic activity is explicitly listed as not established. |
| No ECM crosslinking claim | Pass | Crosslinking appears as LOX-family background or as not established/altered by the current data. |
| No thymic functional claim | Pass | Functional consequences are explicitly listed as not established; future functional work is framed as required before any such interpretation. |
| No therapeutic claim | Pass | No therapeutic language remains in v4.2. |
| No subtype-specific external validation claim | Pass | GSE223049 is repeatedly described as sorted bulk RNA-seq, broad fibroblast/broad epithelial, directionally consistent only, and not subtype-resolved validation. |
| No `possible mediator` language | Pass | Phrase absent. |
| No promotional ranking language | Pass | `most prominent`, `most recurrent`, and `strongest` are absent. |

## Remaining acceptable risky-word contexts

- `remodeling` remains only in prior-literature background and a reference title, not as a claim from the current data.
- `validation` remains in future-validation phrasing, explicit "not subtype-resolved validation" caveats, and local file names such as `scripts/external_validation_gse223049_lox.py`.
- `functional` remains only in explicit limitation/future-work contexts, not as a current-data claim.
- `protein`, `enzymatic`, and `crosslinking` remain only in background, limitations, or future-work contexts.

## Final judgment

`manuscript/LOX_thymus_aging_public_preprint_v4_2_final_safe.md` is the final safe public manuscript. It preserves the scientific content while avoiding causal, protein-level, enzymatic, ECM-crosslinking, thymic-functional, therapeutic, subtype-specific external-validation, mediator, and promotional-ranking overclaims.
